The Court of Appeal has granted permission for Eisai to appeal against a High Court ruling on Nice's decision not to recommend anti-dementia medicines including the company's drug donepezil (Aricept) in newly diagnosed Alzheimer's disease.

In September, Eisai with the support of its marketing partner Pfizer lodged an application to appeal on an issue of procedural fairness. Eisai argued that Nice had refused to disclose a working version of the cost-effectiveness model it had used to determine the value of treatment in patients with mild Alzheimer's disease.

www.eisai.co.uk

The National Prescribing Centre weblog has reviewed a meta-analysis that concluded that cholinesterase inhibitors may not help mild Alzheimer's disease.

www.npci.org.uk/blog